HALO
HALO
US40637H1095
Halozyme Therapeutics, Inc.
Loading chart...

Valuation & History

Quarterly trend of key valuation metrics

Metric
Current (TTM) TTM Baseline
Q2 '26 30.06.2026
Q1 '26 31.03.2026
Q4 '25 31.12.2025
Market & Enterprise Value
Market Cap
12.53B EUR
8.93B EUR
7.66B EUR
7.93B EUR
Enterprise Value
14.41B EUR
10.91B EUR
9.5B EUR
9.94B EUR
Valuation Multiples
Trailing P/E
32.29x
21.58x
21.96x
39.87x
Forward P/E
10.39x
--
--
--
Price to Sales
7.53x
5.37x
5.08x
7x
Price to Book
87.7x
62.18x
34.88x
162.39x
EV/Revenue
8.66x
6.56x
6.29x
8.78x
EV/EBITDA
13.72x
10.43x
10.03x
13.64x
Price to FCF (P/FCF)
37.15x
17.22x
20.16x
38.94x
EV/FCF
42.73x
21.04x
24.99x
48.81x
FCF Yield
2.69%
5.81%
4.96%
2.57%
ende